Plain-English translation of NCT07298005 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can help people with long-COVID who experience severe fatigue and a condition called post-exertional malaise (PEM)—where activity makes symptoms dramatically worse. The study will compare the medication to a placebo (a dummy pill) in about 80 patients to find out if this treatment works and is safe.
Many people recover from COVID but are left with debilitating fatigue and the inability to do normal activities without crashing. There are very few proven treatments for this condition, and this medication may help by supporting how cells produce energy.
You likely qualify if…
You likely don't qualify if…
You would take a daily pill—either the new medication or a placebo—over the course of the study. You'll have regular visits where doctors will check your health, ask about your symptoms and energy levels, and do blood tests. The study involves careful monitoring because the medication affects how your body processes certain drugs and may interact with medicines or supplements you're taking.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Netherlands
Phase
Testing effectiveness
Sponsor
Michele van Vugt
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Khondrion BV
Enrollment target
~80 participants
Started
April 2026
Primary completion
February 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in August 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.